Montrouge, France, February 10 (10:30 p.m. CET) 2023
DBV Technologies invited to participate in an upcoming Investor Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global Biopharma Conference to be held February 13-16, 2023 Daniel Tassé, Chief Executive Officer, will present the Company on Thursday, February 16, 2023 and participate in one-on-one meetings with investors throughout the day.
A live webcast of the Company’s presentation will be available in the Investors and Media section of the Company’s website:
https://wsw.com/webcast/svb8/dbvt/1621296.
The recording will also be available for 90 days after the event on the DBV Technologies website.
About DBV Technologies
DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBVTechnologies food allergy programs include ongoing clinical trials of Viaskin Peanut. DBVTechnologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).
Contact Investors
Anne Pollack
DBV Technologies
+1 857-529-2363
[email protected]
Media contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
[email protected]
Viaskin and EPIT are registered trademarks of DBV Technologies.
Attachment